A separate analysis - the SURMOUNT-1 DXA substudy by Look et al., published in Diabetes, Obesity and Metabolism in 2025 - tracked the body composition effects of tirzepatide over 72 weeks
Case series 1: Under medical oversight, two individuals with Bardet-Biedl syndrome and type 2 diabetes mellitus lost 15% of their total body weight in a 3- and 5-month period, respectively, following a combination therapy of tirzepatide and setmelanotide
Diabetes is complicated enough by itself, and the American health-care system is one more obstacle to good health
Patients who present with both diabetes and PAD can be especially challenging to treat, he added, and the available treatment options are limited
GLP-2 rapidly activates divergent intracellular signaling pathways involved in intestinal cell survival and proliferation in neonatal piglets